PCK2 and hepatocellular carcinoma: This mechanism elucidates a novel regulatory axis of IGF2BP3lac‐PCK2 in lenvatinib‐resistant HCC, highlighting the intricate interplay between metabolic reprogramming and epigenetic modifications.